ROVI obtains second place in a global sustainability rating

ROVI has obtained second place among 360 international pharmaceutical companies in the sustainability rating drawn up by Sustainalytics, a global leader in the evaluation of the Corporate Social Responsibility and Corporate Governance


ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance, business ethics, product management, bribery and corruption and human capital, among others. Thus, the ESG (Environmental, Social and Governance) rating is calculated and furnishes the basis for the company ratings.

In this rating, ROVI obtained the second best rating in the pharmaceutical company category and the 30th of a total of 750 companies in the sector, which includes biotechnology companies and pharmaceutical and health equipment laboratories.

We are proud to see that the management of ROVI, a day-to-day reflection of the company’s values, has received such a high sustainability rating.

No votes yet
 
Related
ROVI REACHED 201.9 MILLION EUROS OF REVENUE IN THE FIRST POST-PANDEMIC QUARTER Operating revenue decreased by 2% to 201.6 million...
3 min
10/05/2023
ROVI COMMENCES CLINICAL DEVELOPMENT OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE (LETROZOLE LEBE) The objective of the new...
6 min
25/04/2023
  Madrid, 12 April, 2023 The Universidad Pontificia Comillas, in collaboration with Laboratorios Farmacéuticos ROVI, has created...
3 min
12/04/2023